Johnson & Johnson
Income Statement
| Line Item | FY2017 | FY2016 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2008 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $76.45B | $71.89B | $74.33B | $71.31B | $67.22B | $61.59B | $61.90B | $63.75B |
| Consumer Health | $13.60B | $13.31B | — | — | — | — | — | — |
| Pharmaceutical / Innovative Medicine | $36.26B | $33.46B | — | — | — | — | — | — |
| Medical Devices / MedTech | $26.59B | $25.12B | — | — | — | — | — | — |
| Cost of Revenue | $25.44B | $21.54B | $22.75B | $22.34B | $21.66B | $18.79B | $18.45B | $18.51B |
| Gross Profit | $51.01B | $48.54B | $51.59B | $48.97B | $45.57B | $42.80B | $43.45B | $45.24B |
| Gross Margin | 66.7% | 67.5% | 69.4% | 68.7% | 67.8% | 69.5% | 70.2% | 71.0% |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | — | — | — | — | — |
| SG&A Expense | $21.52B | $21.20B | $21.95B | $21.83B | $20.87B | $19.42B | $19.80B | $21.49B |
| Operating Income | $18.61B | $19.75B | $21.59B | $16.41B | $14.96B | $17.70B | $16.58B | $17.36B |
| Operating Margin | 24.3% | 27.5% | 29.0% | 23.0% | 22.2% | 28.7% | 26.8% | 27.2% |
| Interest Expense | $934.0M | $552.0M | $533.0M | $482.0M | $532.0M | $455.0M | $451.0M | $435.0M |
| Pretax Income | $17.67B | $19.20B | $20.56B | $15.47B | $13.78B | $16.95B | $15.76B | $16.93B |
| Income Tax Expense | $16.37B | $3.79B | $4.24B | $1.64B | $3.26B | $3.61B | $3.49B | $3.98B |
| Net Income | $1.30B | $15.41B | $16.32B | $13.83B | $10.85B | $13.33B | $12.27B | $12.95B |
| Net Margin | 1.7% | 21.4% | 22.0% | 19.4% | 16.1% | 21.7% | 19.8% | 20.3% |
| EPS (Basic) | $0.48 | $5.56 | $5.80 | $4.92 | $3.94 | $4.85 | $4.45 | $4.62 |
| EPS (Diluted) | $0.47 | $5.48 | $5.70 | $4.81 | $3.86 | $4.78 | $4.40 | $4.57 |
| Shares Outstanding (Basic) | 2.69B | 2.77B | 2.82B | 2.81B | 2.75B | 2.75B | 2.76B | 2.80B |
| Shares Outstanding (Diluted) | 2.75B | 2.81B | 2.86B | 2.88B | 2.81B | 2.79B | 2.79B | 2.84B |
| Dividends Per Share | $3.32 | $2.95 | $2.76 | $2.59 | $2.40 | $2.11 | $1.93 | $1.80 |